Acmos Inc.
As of September 16, 2026: Matters concerning the controlling shareholders, etc.
As for the status of controlling shareholders, Consew Co., Ltd. holds 24.88% of our voting rights. The company aims to keep personnel, funding, and transactions with related parties as separated as possible, and no related-party transactions occurred during the 35th term. Chairman Emeritus Iijima is also a representative of that company. We plan to continue this policy going forward.
Key Figures
- Controlling shareholder voting rights: 24.88％
- Chairman of the Representative Directors: Hideyuki Iijima (Representative Director of Conceive & Eye Co., Ltd.)
- Coverage period: 35th term (2025/7/1–2026/6/30)
AI要約
Overview of controlling shareholder relationships
This document discloses matters concerning controlling shareholders, and as of June 30, 2026, Conceive & Eye Co., Ltd. holds 24.88% of Acmos Co., Ltd.'s voting rights. The company engages in investment business as its main line of business, and Acmos is an investee of that company. Chairman of the board, Hideyuki Iijima, also serves as a director of that company, and that company owns 100% of Acmos' issued shares.
Transaction relationships and policy
We make independent decisions in determining business activities and management strategy, and we maintain a policy to minimize personal, funding, and transaction relationships with parent companies or the like. We plan to continue this policy. There are no transactions with controlling shareholders during the 35th term (from July 1, 2025 to June 30, 2026).
Acmos Co., Ltd.
Company overview · Stock price · Financial data · All IR
